- Home
- LGVN vs LVTX Comparison
LGVN vs LVTX Comparison
Compare LGVN & LVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LGVN
- LVTX
- Stock Information
- Founded
- LGVN 2014
- LVTX 2016
- Country
- LGVN United States
- LVTX Netherlands
- Employees
- LGVN N/A
- LVTX N/A
- Industry
- LGVN Medicinal Chemicals and Botanical Products
- LVTX Biotechnology: Pharmaceutical Preparations
- Sector
- LGVN Health Care
- LVTX Health Care
- Exchange
- LGVN Nasdaq
- LVTX Nasdaq
- Market Cap
- LGVN 27.6M
- LVTX 30.0M
- IPO Year
- LGVN 2021
- LVTX 2021
- Fundamental
- Price
- LGVN $1.61
- LVTX $1.36
- Analyst Decision
- LGVN Strong Buy
- LVTX Hold
- Analyst Count
- LGVN 3
- LVTX 3
- Target Price
- LGVN $8.67
- LVTX $3.17
- AVG Volume (30 Days)
- LGVN 118.8K
- LVTX 59.6K
- Earning Date
- LGVN 05-13-2025
- LVTX 05-20-2025
- Dividend Yield
- LGVN N/A
- LVTX N/A
- EPS Growth
- LGVN N/A
- LVTX N/A
- EPS
- LGVN N/A
- LVTX N/A
- Revenue
- LGVN $2,392,000.00
- LVTX $11,982,000.00
- Revenue This Year
- LGVN $1.30
- LVTX N/A
- Revenue Next Year
- LGVN $19.15
- LVTX N/A
- P/E Ratio
- LGVN N/A
- LVTX N/A
- Revenue Growth
- LGVN 237.38
- LVTX 77.01
- 52 Week Low
- LGVN $0.77
- LVTX $0.85
- 52 Week High
- LGVN $6.40
- LVTX $3.20
- Technical
- Relative Strength Index (RSI)
- LGVN 55.99
- LVTX 62.76
- Support Level
- LGVN $1.45
- LVTX $1.03
- Resistance Level
- LGVN $1.46
- LVTX $1.43
- Average True Range (ATR)
- LGVN 0.14
- LVTX 0.09
- MACD
- LGVN 0.02
- LVTX 0.02
- Stochastic Oscillator
- LGVN 100.00
- LVTX 80.98
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.
About LVTX LAVA Therapeutics N.V.
LAVA Therapeutics NV isa clinical stage immuno-oncology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer. Company's pipeline include's products such as LAVA-1266, LAVA-1427, LAVA-1433, LAVA-1207, PF08046052, JNJ89853413.